Type 2 diabetes mellitus (T2DM) is a chronic disease in which a hyperglycemic state is induced by insulin resistance. While there are numerous treatment options available to manage T2DM, many patients require changes in therapy throughout treatment, as well as multiple medications. The sodium/glucose cotransporter 2 (SGLT2) inhibitors, canagliflozin and dapagliflozin, offer a therapeutic alternative in T2DM management through the utilization of a unique mechanism of action to provide intensified glycemic control. This article will evaluate the safety and efficacy of dapagliflozin in the management ofT2DM.
Ruhe A, Muhlenkamp R, Brown A, Blum E, Hrometz SL. Dapagliflozin: A Newly Approved SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. PAW Review. 2014 Jul 01; 5(3):Article 1 2-7 . Available from: https://digitalcommons.onu.edu/paw_review/vol5/iss3/1.